Back to Search
LAUREN HUDAK, M.D., M.P.H.
M.D., M.P.H.
Emergency Medicine Physician
NPI: 1508127093IndividualAccepts Medicare
Specialties, Licenses & Credentials
Emergency Medicine PhysicianPrimary
Emergency Medicine
Code: 207P00000X
072766(GA)
CMS Specialties
PrimaryEMERGENCY MEDICINE
Education
EMORY UNIVERSITY SCHOOL OF MEDICINE
Class of 2012
Research & Publications (7)
Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro.
PMID 19594733·BJU Int·2010
8-other
Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells.
PMID 19473483·BMC Cancer·2009
8-other
The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.
PMID 18657224·J Cell Mol Med·2009
7-preclinical
Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix.
PMID 19067765·J Cell Mol Med·2009
8-other
Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
PMID 18698487·Int J Mol Med·2008
8-other
[Preclinical studies on the influence of the tyrosine kinase inhibitor AEE788 on malignant properties of renal cell carcinoma cells].
PMID 18688594·Urologe A·2008
8-other
New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma.
PMID 18266964·J Cell Mol Med·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 531 ASBURY CIR, SUITE N340
ATLANTA, GA 30322 - Phone
- (404) 778-5975
Quick Facts
- NPI
- 1508127093
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 14
- Publications
- 7
Are you this provider?
Claim Your Profile